Cost-effectiveness analyses using real-world data: an overview of the literature
Author:
Affiliation:
1. Bayer plc, Reading, UK;
2. Bayer AG, Berlin, Germany;
3. Université Paris-Dauphine, PSL Research University, Paris, France;
4. Creativ-Ceutical, Paris, France;
5. Aix-Marseille University, Marseille, France
Funder
Error! Hyperlink reference not valid.
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1588737
Reference37 articles.
1. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
2. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
3. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
4. Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial)
5. Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors;Value in Health;2024-07
2. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World;The Oncologist;2024-03-23
3. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process;Journal of Pharmacy & Pharmaceutical Sciences;2024-02-28
4. How the structural determinants of health inequities impact access to prescription medication for pregnant women in Australia: a narrative review;The Lancet Regional Health - Western Pacific;2024-01
5. Hot topics in allergen immunotherapy, 2023: Current status and future perspective;Allergy;2023-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3